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There is increasing evidence of a systemic inflammatory response associated with malignancy, which may have an impact on both
drug disposition and resistance to cytotoxic therapy. The impact of inflammation on drug disposition was studied in mice bearing a
number of common tumour xenografts. C57BL/6 mice were inoculated with tumour xenografts. Hepatic expressions of Cyp3a and
drug transporters were analysed at the mRNA, protein and functional levels (Cyp3a only). Circulating serum cytokines and the
hepatic expression of acute phase proteins (APPs) were measured. Intratumoral levels of multidrug resistance genes were
determined. Tumour xenografts elicited an inflammatory response that coincided with repression in hepatic Cyp3a11 activity and the
expression of a number of hepatic drug transporters. With tumour growth, a progressive reduction in hepatic Cyp3a11 mRNA
expression was seen. Conversely, an increase in the hepatic APP expression and circulating interleukin (IL)-6 levels was observed.
Furthermore, a correlation was seen between increased intratumoral expression of the multidrug resistance gene, Mdr1a, and levels
of circulating IL-6. Malignancy results in reduced hepatic drug disposition that correlates with an associated inflammatory response.
Reduction of inflammation may improve the clinical outcome for patients receiving chemotherapeutic agents that undergo hepatic
metabolism.
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The pharmacokinetics (PKs) of chemotherapeutic drugs vary
considerably between patients, and because of the narrow
therapeutic index of most anticancer agents, results in their
inherent lack of safety. Variability in the PKs of anticancer agents
can be attributed to a number of factors including comedications,
environmental factors, genetic polymorphisms and certain disease
states. These factors can have an impact on drug disposition,
resulting in either ineffective drug doses or excessive toxicity
(Thummel and Wilkinson, 1998; Schuetz, 2004). This concept is
supported by a study demonstrating that reductions in CYP3A4
activity in patients with advanced cancer were correlated to an
increased plasma concentration of the inflammatory mediators
interleukin (IL-)6 and C-reactive protein (CRP) (Rivory et al, 2002;
Slaviero et al, 2003). This was associated with reduced clearance
and increased toxicity from docetaxel, a well-characterised
substrate for CYP3A4.
The presence of a tumour-induced inflammatory response is
increasingly being recognised in patients with solid tumours
(Mahmoud and Rivera, 2002; Assenat et al, 2006). Clinically,
tumour-induced inflammation is characterised by weight loss,
night sweats and fevers, as exemplified by the B symptoms
associated with lymphoma. Furthermore, the presence of systemic
inflammation is recognised as a predictor of worse outcome in
patients with malignancy. Raised levels of CRP, an acute phase
protein (APP), and proinflammatory cytokines, especially IL-6, are
strong, independent prognostic factors for survival in a number of
tumour types including breast, renal cell, prostate and colorectal
cancers (Jamieson et al, 2005; Al Murri et al, 2006; Crozier et al,
2006; Lamb et al, 2006; McArdle et al, 2006). IL-6 has further been
implicated in promotion of tumour growth, invasion and
metastasis, and the development of drug resistance (Kato et al,
1998; Esper and Harb, 2005).
The relationship between inflammation and repression of P450
activity, in particular CYP3A4, has been extensively studied both
in vitro and in vivo (Chen et al, 1994; Carcillo et al, 2003; Haack
et al, 2003). These studies consistently illustrate reduced hepatic
expression of CYPs in the presence of acute inflammation,
mediated primarily by the proinflammatory cytokines IL-6, IL-1b
and tumour necrosis factor-a (TNF-a), resulting in reduced drug
metabolism and clearance (Morgan, 1997, 2001; Fang et al, 2004).
More recently, acute inflammation has been shown to also impact
on the expression and activity of hepatic transporters. Uptake of
drugs from the basolateral surface of the hepatocytes into the cell is
facilitated by the Na
þ-taurocholate cotransporting polypeptide
(NTCP) and organic anion-transporting polypeptide (OATP)
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sfamilies. Following metabolism, efflux of metabolites across the
canalicular surface of the hepatocyte into bile is facilitated by
members of the ABC family of transporters, specifically the bile salt
export pump (Bsep), multidrug resistance-associated protein
(MRP2) and members of the multidrug resistance (MDR) family.
Efflux across the basolateral surface of the hepatocyte back into the
circulation is mediated by MRP3 and MRP4 (Kullak-Ublick et al,
2004; Maher et al, 2005). These transporters are responsible for the
uptake and elimination of a number of chemotherapeutic agents
and their disruption may lead to an increased risk of adverse events
(Chandra and Brouwer, 2004).
Cytokines, in particular IL-6, reduce the mRNA and protein
expressions of some hepatic transporters in vivo, and function
in vitro (Hartmann et al, 2001; Lee and Piquette-Miller, 2001;
Sukhai et al, 2001; Hartmann et al, 2002). Conversely, in tumours,
studies have demonstrated an increase in the expression of some
ABC superfamily transporters on tumour cells in response to IL-6,
where they produce the multidrug-resistant tumour phenotype
(Conze et al, 2001; Duan et al, 2002).
In the current study, we have tested the hypothesis that a
reduction in both hepatic Cyp3a11 and hepatic transporter
expression occurs in the presence of cancer, and is a result of a
cytokine release associated with extra-hepatic malignancy.
Furthermore, we investigated the effect of tumour-induced
inflammation on the expression of multidrug-resistant tranporters
within the tumour tissue itself.
MATERIALS AND METHODS
Animal experimentation
All animal protocols and studies were conducted in accordance
with the guidelines of the Australian Council on Animal Care and
approval was obtained from the Westmead Hospital Animal Ethics
Committee before commencement of experimentation. C57BL/6
mice were obtained from the Animal Resources Centre, Perth,
Western Australia. Animals were kept in a temperature-controlled
facility with 12-h light/dark cycles and were fed a standard chow
diet and allowed water ad libitum. The condition of the animals
was assessed daily by trained animal handlers to ensure that they
remained well and active during the course of the experimentation.
Eight- to ten-week-old male mice were aseptically inoculated
with either 0.3ml suspension of Englebreth-Holm-Swarm (EHS)
sarcoma into the right quadriceps muscle, 3.8 10
6 B16 melanoma
cells (gift from Peter Parson, Queensland Institute of Medical
Research, Brisbane, QLD, Australia) or 3.8 10
6 E0771 breast
cancer cells (gift from Robin Andersen, Peter MacCallum Cancer
Centre, Melbourne, VIC, Australia) suspended in 0.3ml of PBS
subcutaneously into the right flank. Control animals were
inoculated with the vehicle alone.
Mice were weighed and calliper measurements of the sub-
cutaneous tumour were made daily. The volume of tumour (in
mm
3) was calculated using the equation volume¼0.5 
(width breadth height). Tumour mass reached approximately
3g or 10% of total body weight after approximately 3 weeks. Mice
were anaesthetised with ketamine and xylazine (30 and 8mgml
 1,
respectively in water) before cardiac puncture for the collection
of blood. The liver was immediately harvested and snap-frozen in
liquid nitrogen and stored at  701C. Serum was snap-frozen in
aliquots in liquid nitrogen and then stored at  701C. For the time-
course experiments, mice inoculated with the EHS sarcoma were
harvested at four different time points: days 4, 7, 11 and 18.
Determination of mRNA expression
Total RNA was isolated from mouse liver and tumour using Trizol
reagent (Invitrogen, Mulgrave, Australia) and treated with DNase I
(Ambion, Austin, TX, USA) according to the manufacturer’s
protocols. Complementary DNA was synthesized from 5mg of total
RNA with SuperScript III cDNA First-Strand Synthesis System
(Invitrogen) using random hexamer primers. Taqman or SYBR
green protocols were used to amplify cDNAs of interest by real-
time quantitative PCR (Q-PCR) using a Rotor-Gene 3000 (Corbett
Research, Sydney, NSW, Australia). Primers were obtained from
Invitrogen and primer/Taqman probes from Applied Biosystems
(Forster City, CA, USA). Messenger RNA levels were normalised to
18S mRNA expression. Normalisation to 18S, B2M and C36B4
mRNA housekeeping genes gave comparable results. Primer and
probe sequences are available on request.
Western blot analysis
Extraction and preparation of reduced proteins from liver tissue
were performed as described previously (Ip et al, 2003). For
immunoblotting, 15mgo fp r o t e i nw a sl o a d e da n dr e s o l v e do n
7% sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) for 2h under reducing conditions and then transferred
to polyvinylidine difluoride membranes. Membranes containing
transporter proteins were then cut into half and the upper portion
(mol. wt. 472kDa) was incubated with either cMOAT/MRP2 (clone
M2III6) antibody (Signet, Debham, MA, USA) or MRP3 (clone M3II-
9) antibody (Signet), followed by a peroxidase-conjugated secondary
antibody (Sigma-Aldrich, Castle Hill, NSW, Australia). To control for
variability in protein loading, the lower portion of the membrane
(mol. wt. o72kDa) was incubated with the anti-b-actin clone AC15
antibody (Sigma-Aldrich), followed by the secondary antibody.
Mouse Cyp3a proteins were detected with a polyclonal rabbit anti-rat
Cyp3a antibody (Chemikalien, Gertenbach, Germany). Proteins were
visualised by SuperSignal West Pico chemiluminescence kit (Pierce
Endogen, Rockford, IL, USA) and quantified using densitometric
analysis.
Midazolam sleep test
To determine whether the transcriptional repression of murine Cyp3a
genes resulted in altered Cyp3a function, activity was assessed using
the midazolam sleep time, a specific substrate for Cyp3a enzymes
(Watanabe et al, 1998). Before harvesting, tumour-bearing and
control mice were injected intraperitoneally with midazolam
(12mgkg
 1). Mice were deemed to be asleep when loss of righting
reflex was observed, and awake when this reflex returned.
Measurement of IL-1b,T N F - a and IL-6 levels
Cytokine levels in the serum of tumour-bearing and control mice
were measured using the Quantikine high-sensitivity mouse IL-1b,
TNF-a and IL-6 immunoassays as per the manufacturer’s
instructions (R&D Systems Europe, Abingdon, Oxon, UK).
Statistical analysis
All studies were performed using groups of nX4 mice. Differences
between tumour-bearing and non-tumour-bearing mice were
determined by one-way analysis of variance and logistic regression
analysis, with Po0.05 considered to be statistically significant.
Data were log-transformed before analysis in order to stabilise
variance if deemed necessary. Analysis was performed using SPSS
version 11.5 (SPSS Inc., Chicago, IL, USA).
RESULTS
Impact of tumour on Cyp3a11 expression and function
To determine whether the presence of extra-hepatic malignancy
affects the activity of hepatic Cyp3a11, mice were injected with a
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snumber of tumour xenografts or vehicle. Following tumour
inoculation, mice maintained good health and activity levels with
no net weight loss observed. No adverse events were noted during
the study period and no mice died during the experiment. The time
to harvest from tumour implantation was as follows melanoma B16,
20 days; breast E0771, 16 days; and EHS sarcoma, 24 days. The
average tumour volume of each tumour type at harvest was as
follows melanoma B16, 2290mm
3 (2216–3596mm
3); breast
E0771, 2177mm
3 (228–7399mm
3); and EHS sarcoma, 4690mm
3
(3188–6459mm
3).
On Q-PCR, the presence of malignancy resulted in a significant
repression in hepatic Cyp3a11 mRNA compared with controls for
all tumour types (Figure 1A). These results were confirmed at the
protein level by western analysis (Figure 1B and C). To determine
whether repression of Cyp3a11 resulted in altered Cyp3a-mediated
drug metabolism, midazolam-induced sleeping times were mea-
sured. Significantly prolonged sleeping times were observed for all
tumour types compared with controls. In particular, mice bearing
implanted breast E0771 cells slept 4.6 times longer, and melanoma
B16-bearing mice slept 3 times longer than controls (Figure 1D).
Evaluation of tumour-induced inflammation
As described previously, a systemic inflammatory response has
been shown to be associated with the repression of Cyp3a activity
(Shedlofsky et al, 1994; Mayo et al, 2000; Frye et al, 2002). In order
to determine whether the presence of malignancy induced a
systemic inflammatory response, the mRNA expression of the
hepatic acute phase reactants, serum amyloid protein (Sap) and
metallothionein were measured in tumour-bearing mice compared
with controls. Additionally, the cytokines contributing to this
proinflammatory state were determined. Implantation of EHS
sarcoma resulted in a significant increase in mRNA expression of
both acute phase genes compared with controls (Figure 2A and B).
A significant increase in metallothionein mRNA expression was
observed in mice bearing the breast cancer and melanoma
xenografts. A trend was observed for the upregulation of Sap in
mice bearing melanoma (P¼0.08) and breast cancer (P¼0.06)
xenografts compared with controls. The proinflammatory cyto-
kines IL-1b, TNF-a and IL-6 were quantified using ELISA. No
significant differences were observed in the circulating levels of
IL-1b and TNF-a between control and tumour-bearing mice (data
not shown). However, the level of IL-6 was significantly elevated in
all tumour models compared with controls (Figure 2B).
Regulation of hepatic transporter genes in the presence of
extra-hepatic malignancy
As acute inflammation represses the expression of hepatic
transporters, the expression levels of hepatic transporters in the
presence of tumour-induced inflammation were determined
(Hartmann et al, 2001, 2002; Lee and Piquette-Miller, 2001; Sukhai
et al, 2001). The mRNA expression levels of relevant transporters
were determined in mice bearing EHS sarcoma tumours and
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Figure 1 Effect of extra-hepatic malignancy on hepatic Cyp3a11 mRNA expression and Cyp3a protein and activity in vivo. Mice (n¼4–5 per group) were
injected with vehicle (control), breast E0771, melanoma B16 or EHS sarcoma xenografts as described in Materials and Methods and killed after 3 weeks, or
when the viability of the mouse was threatened. (A) Relative quantification of hepatic Cyp3a11 gene expression in tumour-bearing and control mice.
Hepatic Cyp3a11 mRNA levels were determined by Q-PCR and normalised to 18S RNA gene expression. (B, C) Quantification of Cyp3a protein in the
liver of tumour-bearing and control mice by western blot analysis using a rabbit anti-rat Cyp3a antibody. Cyp3a protein expression was quantified by
densitometry and then normalised to b-actin protein expression. (D) Measurement of Cyp3a-mediated metabolism of midazolam in tumour-bearing and
control mice. Mice were administered 12mgkg
 1 midazolam (i.p.) and the period of sedation was measured. Box and whisker plot, median and interquartile
range. Columns, average of four or five mice; bars, s.e.m. *Po0.05; **Po0.001.
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scompared with controls by Q-PCR. In tumour-bearing mice, the
hepatic expression levels of Mdr2, Mrp2, Mrp3, Ntcp, Oatp2,
Oatp-c and Bcrp were significantly reduced compared with
controls (Figure 3A). The expression of Mdr1a and Bsep was not
significantly altered. Immunoblotting confirmed the repression of
Mrp2 and Mrp3 at the protein level (Figure 3B and C).
Relationship between tumour growth and diminished
Cyp3a11 expression
In order to assess whether the repression of hepatic Cyp3a11
mRNA expression and the presence of inflammation were
dependent on tumour growth or the presence of malignancy per
se, mice were injected with EHS sarcoma and harvested at different
time points. A progressive decrease in the relative expression of
hepatic Cyp3a11 mRNA levels was observed at days 4, 7, 11 and
18 between control and tumour-bearing mice (Figure 4A). A
significant increase in the hepatic mRNA expression of Sap was
also observed at each time point in tumour-bearing mice
compared with controls (Figure 4B). Furthermore, a significant
increase was seen in circulating IL-6 levels in the serum of tumour-
bearing mice compared with controls at days 7, 11 and 18
(Figure 4C). A statistically significant positive rank correlation of
0.6 was observed between circulating IL-6 levels and Sap. A trend
was observed between increasing serum levels of IL-6 and reduced
hepatic Cyp3a11 mRNA expression (R¼ 0.407, P¼0.07).
Impact of increasing tumour growth on drug transporter
expression
As administration of exogenous IL-6 to cancer cells in vitro
induces drug resistance, the expression of multidrug resistance
genes was assessed within the tumour at different time points
(Borsellino et al, 1995; Conze et al, 2001). A significant increase in
the mRNA levels of the multidrug-resistance transporter, Mdr1a,
was observed within the tumour tissue at day 18 compared with
day 11 (Figure 4D). This was associated with increasing levels of
both circulating IL-6 (Po0.05; 95% CI: 1.2–2.9) and mRNA
expression levels of IL-6 within the tumour itself (Po0.05; 95% CI:
1.0–2.6). Combined with the observed decrease in expression of
MRPs and other ABC transporters in the livers of tumour-bearing
mice (Figure 2A), this finding highlights the divergent regulation
of drug transporters in cancerous tissues compared with other
organs in the body. No change was observed in the intratumoral
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Figure 2 Assessment of inflammation in mice bearing tumour xenografts. Mice (n¼4–5 per group) were injected with (vehicle) control or breast E0771,
melanoma B16 or EHS sarcoma xenografts as described in Materials and Methods. (A) Relative quantification of hepatic acute phase protein, Sap, in tumour-
bearing and control mice. Hepatic Sap mRNA levels were determined by Q-PCR and normalised to 18S RNA expression. (B) Serum concentration of IL-6
in tumour-bearing and control mice. Sera were analysed for IL-6 concentrations by ELISA. Box and whisker plot, median and interquartile range. *Po0.05;
**Po0.001.
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Figure 3 Effect of extra-hepatic malignancy on expression of hepatic
drug transporters and Mrp2 and Mrp3 protein expression in vivo. Mice
(n¼4–6 per group) were injected with vehicle control or EHS sarcoma
and killed after 3 weeks or when the viability of the mouse was threatened
as described in Materials and Methods. (A) Quantification of hepatic
transporter gene expression in tumour-bearing and control mice. mRNA
expression of hepatic drug transporters was determined by Q-PCR and
normalised to 18S RNA mRNA expression. (B, C) Quantification of Mrp2
and Mrp3 proteins in the liver of tumour-bearing and control mice by
western blot analysis. Expression of Mrp2 and Mrp3 proteins was quantified
by densitometry and then normalised to b-actin protein expression.
Columns, average of five or six mice; bars, s.e.m. *Po0.05; **Po0.001.
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shown).
DISCUSSION
Alterations in the expression of enzymes and transport proteins
involved in hepatic drug disposition can have an important influence
on the susceptibility of organs and tissues to the therapeutic and toxic
effects of anticancer drugs. The first aim of this study, therefore, was
to assess the effect of extra-hepatic malignancy on hepatic Cyp3a
mRNA expression and activity, and whether this was associated with
a tumour-induced acute phase response.
We have shown in murine models of a number of common
malignancies that there is a significant repression of hepatic
Cyp3a11 mRNA expression in tumour-bearing mice compared
with controls, functionally reflected by a prolongation of the
sedative effect of midazolam, a CYP3A substrate. This study
further expands on previous experiments from our group in which
a transgenic mouse model of human CYP3A4 regulation was used
to demonstrate that the presence of tumour resulted in down-
regulation of the CYP3A4 transgene, which was linked to a
systemic acute phase response. Furthermore, IL-6 was localised to
the tumour and not the liver in tumour-bearing animals,
suggesting that the tumour or its associated stroma is the source
of IL-6. As a result of this study, a mechanistic link was suggested
between tumour-derived cytokines and impaired drug metabolism
(Slaviero et al, 2006). While repression of hepatic Cyp3a11 at the
mRNA, protein and functional level was found in majority of
tumour models in this study, the tumour-associated inflammatory
response was not equal between these models. This was not an
unexpected result. It is well described that certain malignancies,
including ovarian, myeloma and renal cell carcinoma, elicit a more
pronounced inflammatory response than other tumours and this
may account for the differences in the cytokine profiles observed
(Nash et al, 1999). The hepatic mRNA expression levels of Sap
exhibited a varied response and this suggests that altered hepatic
gene regulation in the presence of malignancy is complex, and that
the genes affected by inflammation associated with malignancy
may be impacted upon by divergent cytokine profiles and
regulatory mechanisms.
While the cytokines contributing to the systemic inflammatory
response associated with malignancy have not been extensively
characterised, the cytokines involved in the repression of murine
Cyp3a11 in acute inflammation have been extensively studied both
in vitro and in vivo. In vitro studies in hepatoma cell lines illustrate
the downregulation of Cyp3a11 exposed to the proinflammatory
cytokines IL-6, IL-1b and TNF-a (Lee and Piquette-Miller, 2001;
Sukhai et al, 2001). Furthermore, the inducible expression of
CYP3A4 by rifampicin in human primary hepatocytes in culture is
abrogated by the administration of IL-6, suggesting a central role
of IL-6 in the repression of CYP3A (Muntane-Relat et al, 1995;
Guillen et al, 1998). On administration of these cytokines to
rodents, reproducible reductions of Cyp3a mRNA expression with
IL-1b, TNF-a and especially IL-6 were observed (Ghezzi et al,
1986a,b; Ferrari et al, 1993). Furthermore, in in vivo studies in IL-
6-deficient mice, no repression in Cyp3a11 was seen on treatment
with turpentine or tuberculosis vaccine (Siewert et al, 2000).
Moreover, deletion of the IL-1b and TNF-a receptors in vivo had
little or no effect on Cyp3a11 downregulation (Ashino et al, 2004).
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Figure 4 Time-course study examining the impact of tumour growth on hepatic drug metabolism, tumour drug disposition and hepatic inflammatory
response. Mice (n¼4–6) were injected with (vehicle) control or EHS sarcoma as described in Materials and Methods and killed at days 4, 7, 11 and 18. (A)
Relative quantification of hepatic Cyp3a11 expression in tumour-bearing mice compared with control mice at four different time points. Hepatic Cyp3a11
mRNA levels were determined by Q-PCR and normalised to 18S RNA gene expression. (B) Relative quantification of hepatic Sap expression in tumour-
bearing and control mice at four different time points. The expression of hepatic Sap was determined by Q-PCR and normalised to 18S RNA mRNA. (C)
Serum concentration of IL-6 in tumour-bearing and control mice at advancing time points. Sera were analysed for IL-6 concentrations by ELISA. (D) Relative
quantification of Mdr1a gene expression within the implanted EHS tumour at days 11 and 18. Tumoral Mdr1a mRNA expression was determined by Q-PCR
and normalised to 18S RNA gene expression. These time points were chosen due to the small size of the tumour mass before day 11. Points, average of
4–6 mice; bars, s.e.m., *Po0.05; **Po0.001.
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sTherefore, from both preclinical and clinical studies, IL-6 appears
to play a central role in the downregulation of the CYP3A
subfamily of enzymes in response to acute inflammation,
consistent with our results (Aitken et al, 2006).
The next aim of this study was to assess the impact of tumour-
associated inflammation on the expression of hepatic transporters
in order to ascertain whether derangement of drug disposition
represents a more global phenomena occurring within the liver,
involving more than drug metabolism. This is the first report of
the involvement of drug transporters in the altered drug response
in malignancy, specifically, the transcriptional downregulation of
the hepatic mRNA expression of Mdr2, Mrp2, Mrp3, Ntcp, Oatp2,
Oatp-c and Bcrp. This represents a widespread repression of drug
transport within the liver with transporters mediating both uptake
and efflux from the affected hepatocyte. These findings are
consistent with previously reported in vitro and in vivo models
of acute inflammation in which IL-6 is reported to be the major
contributor to the repression of hepatic transporter mRNA
expression (Siewert et al, 2000; Hartmann et al, 2001; Teng and
Piquette-Miller, 2005). The mRNA expression of Mdr1a was not
anticipated to be reduced, based on the findings of previous
studies that report the importance of post-translational factors
in Mdr1a expression (Cornwell, 1991). We did not observe a
repression of Bsep mRNA expression in tumour-bearing animals,
which was contrary to previous studies in acute inflammation.
Bsep expression is reported to be reduced with the administration
of IL-6 and endotoxin to mice; however, the mechanism by which
Bsep is regulated remains unclear and it is possible that cytokines
associated with malignancy may not affect Bsep mRNA expression
(Teng and Piquette-Miller, 2005). These findings further emphasise
the global repression of hepatic drug disposition in the setting of
malignancy and warrant further investigation particularly asses-
sing the functional impact of these transporters on the distribution
and elimination of cytotoxic agents within the liver.
The final aspect of this study was to determine the effect of
tumour size on Cyp3a expression and plasma cytokine concentra-
tions. We have clearly shown that the transcriptional down-
regulation of Cyp3a11 mRNA is dependent on tumour growth.
This was also true of the acute phase response with progressive
increases in hepatic Sap mRNA and levels of circulating IL-6
observed at each advancing time point. Furthermore, we observed
an increase in the expression of Mdr1a within the tumour of mice
bearing the EHS sarcoma from day 11 to day 18. This was in direct
contrast with the mRNA expression of Mdr1a within the liver that
is reduced, albeit not significantly. These time-course studies are
novel in that they illustrate that the acute phase response and
subsequent impaired drug metabolism are dependent on tumour
growth. This suggests that the tumour itself, its supporting
vasculature and/or stroma may be the source of IL-6. Furthermore,
our findings suggest an association between circulating IL-6 levels
and the upregulation of multidrug resistance genes within the
tumour. This is consistent with in vitro studies in which the
autocrine production of IL-6 in breast cancer cells was demon-
strated to increase MDR expression within the tumor cells
themselves (Borsellino et al, 1995; Conze et al, 2001).
The findings of the present study are unlikely to be the result of
the mice being perturbed from the tumour implantation per se,a s
they remained in good health throughout the experiment. We have
shown that tumor-bearing animals have evidence of a systemic
inflammatory state and that this contributes to a global derange-
ment of hepatic drug handling. Furthermore, we have shown that
this is not specific for a particular tumour type but is a general
phenomenon that applies in varying degrees to a number of
tumour types. This is in the context of increased multidrug
resistance gene expression within the tumour itself. While the
molecular mechanisms are not well understood, this study raises
the possibility that patients with cancer who develop an
inflammatory response may have reduced metabolism and tumour
chemosensitivity and/or increased toxicity. Serum concentrations
of APPs or cytokines could potentially be used as predictive factors
for hepatic handling of cytotoxic drugs. In addition, reversal of the
inflammatory process before administration of chemotherapy
could potentially negate the deranged drug phenotype and
improve treatment tolerance and efficacy. These animal models
create an experimental platform to assess such reversal strategies
that could guide future clinical studies.
Additional studies are required to ascertain whether a correla-
tion exists between reduced expression of hepatic transporters and
impaired drug handling in vivo. Further work is also needed to
investigate the interplay of cytokine signalling pathways with
transcription factors known to be relevant to drug-metabolising
and transporting genes such as hepatocyte nuclear factor-4a, signal
transducer and activators of transcription 3, CCAAT enhancer
binding proteins and the pregnane X receptor, in order to further
understand the mechanism by which IL-6 regulates drug clearance
in the presence of tumours (Roy-Chowdhury et al, 2003; Tirona
et al, 2003).
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